title: Side effects of 2 different dexamethasone courses for preterm infants at risk of chronic lung disease: a randomized trial.
abstract: OBJECTIVE
  We hypothesized that a pulsed course of dexamethasone would result in better linear growth than a 42-day reducing course in preterm infants at risk for chronic lung disease of prematurity.
  
  
  METHODS
  Forty infants with a birth weight of < or =1,250 g who required mechanical ventilation at 7 days of age were randomly assigned to a repeatable 3-day pulse course of dexamethasone commencing immediately or a 42-day (long) course commencing at 14 days of age if they still required mechanical ventilation and supplemental oxygen. The primary outcome measure was linear growth at 36 weeks' postmenstrual age measured by knemometry.
  
  
  RESULTS
  There was no difference in lower leg length at 36 weeks' postmenstrual age. Infants receiving the pulse course had lower rises in blood pressure, less myocardial hypertrophy, and less adrenal suppression. However, more infants required supplemental oxygen at 28 days' postnatal age (14/18 vs 8/21, P < .05) and 36 weeks' PMA (8/16 vs 5/20, P = .12).
  
  
  CONCLUSIONS
  In preterm infants at risk for chronic lung disease, a pulsed course of dexamethasone has fewer side effects than a long course but may be less effective at preventing chronic lung disease.
authors.affiliation: Department of Pediatrics, National Women's Hospital, Auckland, New Zealand.
authors.forename: F H
authors.initials: FH
authors.lastname: Bloomfield
authors.forename: D B
authors.initials: DB
authors.lastname: Knight
authors.forename: J E
authors.initials: JE
authors.lastname: Harding
mesh_terms: D000280:Administration, Inhalation; D000311:Adrenal Glands / Q000187:drug effects; D000309:Adrenal Insufficiency / Q000517:prevention & control; D000893:Anti-Inflammatory Agents / Q000008:administration & dosage / Q000009:adverse effects*; D001794:Blood Pressure / Q000187:drug effects; D001827:Body Height; D006332:Cardiomegaly / Q000517:prevention & control; D002908:Chronic Disease; D003907:Dexamethasone / Q000008:administration & dosage / Q000009:adverse effects*; D004334:Drug Administration Schedule; D005260:Female; D005938:Glucocorticoids / Q000008:administration & dosage / Q000009:adverse effects*; D006801:Humans; D006973:Hypertension / Q000517:prevention & control; D007231:Infant, Newborn; D007234:Infant, Premature / Q000254:growth & development; D007235:Infant, Premature, Diseases / Q000517:prevention & control*; D019102:Infant, Very Low Birth Weight / Q000254:growth & development; D007866:Leg / Q000254:growth & development; D008171:Lung Diseases / Q000517:prevention & control*; D008297:Male; D010102:Oxygen Inhalation Therapy; D012121:Respiration, Artificial; D012307:Risk Factors; D016896:Treatment Outcome
chemical_list: D000893:Anti-Inflammatory Agents; D005938:Glucocorticoids; D003907:Dexamethasone